Source: Lumiera Health Inc.
  • Lumiera Health (NHP) has signed an MoU to explore a strategic partnership with one of Quebec’s leaders in the natural health industry
  • The MoU will set guidelines for an agreement allowing both Lumiera and its partner to manufacture and sell white label products from their respective portfolio to each other
  • The agreement would provide Lumiera with access to a broad range of products in Natural Health retail stores
  • Lumiera specializes in the development and commercialization of consumer products for the natural health industry
  • Lumiera Health opened trading at C$0.015

Lumiera Health (NHP) has signed an MoU to explore a strategic partnership with one of Quebec’s leaders in the natural health industry.

The purpose of the MoU is to set the guidelines to discuss an eventual agreement that would allow both Lumiera and its Partner to manufacture and sell white label products from their respective portfolio to each other. The potential agreement would include a mutually exclusive supplier agreement, as well as minimum quantity requirements and exclusivity in certain sales channels.

The partner company has been an established leader in Quebec’s Natural Health industry for over 75 years and has a strong presence in the Pharmacy and Big Box retail channels.

Carlos Ponce, CEO of Lumiera, commented on the news.

“This potential partnership is an incredible opportunity for Lumiera. By leveraging our partner’s considerable brand equity and distribution in high-volume retail channels, we can accelerate our growth exponentially. Furthermore, this would give Lumiera access to a broad range of products that have enormous potential in Natural Health retail stores.”

Lumiera specializes in the development and commercialization of consumer products for the natural health industry.

Lumiera Health opened trading at C$0.015.


More From The Market Online

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.